The skeletal impact of cancer therapies

Lucia Bedatsova, Matthew T. Drake

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.

Original languageEnglish (US)
Pages (from-to)1161-1168
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume85
Issue number6
DOIs
StatePublished - Jun 2019

Keywords

  • androgen deprivation therapy
  • aromatase inhibitor
  • bone loss
  • breast cancer
  • myeloma
  • prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The skeletal impact of cancer therapies'. Together they form a unique fingerprint.

  • Cite this